Furegrelate Sodium is being developed as an antiplatelet agent; it prevents coronary artery occlusion and stenosis-induced platelet aggregation; it attenuates the development of hypoxia-induced pulmonary arterial hypertension (PAH) by preserving the structural integrity of the pulmonary vasculature.